

---

## CASE REPORTS

### KODAMAEA OHMERI –AN EMERGING FUNGAL PATHOGEN IN NEONATAL INTENSIVE CARE UNIT

Ashwin Borade\*, Muznah Kapdi\*, Kalpana Suryavanshi\*\*

---

#### Abstract

A yeast-like fungus *Kodamaea ohmeri* is a very rare cause of fungemia with high mortality especially in immunocompromised patients. We report a rare case of *K. ohmeri* fungemia in a premature neonate which was successfully treated with liposomal amphotericin B. The case emphasizes the need for high index of suspicion and timely intervention to diagnose this fungal infection in septic neonates who are not responding to antibiotic therapy in neonatal intensive care unit (NICU).

**Keywords:** Kodamaea ohmeri, Preterm, Liposomal Amphotericin B

#### Introduction

*Kodamaea ohmeri* although formerly considered a contaminant, is now regarded not only as disease causing pathogen but an organism responsible for variety of complications in immunocompromised patients. (1) Most of the preterm neonates are immunocompromised, in addition invasive procedures, intubation, prolonged stay on ventilator and antibiotic usage in neonatal intensive care unit (NICU) predisposes them to systemic fungal infections. (1,2) Our literature search till date reveals that there have been only few published cases of newborn fungemia with *K. ohmeri* worldwide and two in India. (2-6) We present a case of neonatal *K. ohmeri* fungemia that responded to liposomal

amphotericin B.

#### Case Report

A 33 weeks preterm male baby was delivered to a healthy immunocompetent mother by a lower segment caesarean section in view of mother having severe pregnancy induced hypertension (PIH). The birth weight of the child was 1.5kg. He had mild respiratory distress on admission to NICU requiring supplemental oxygen. Umbilical vein was catheterized and he was started on intravenous fluids and intravenous (IV) Cefotaxime and amikacin. The initial septic work up including hemogram, C-reactive protein and blood cultures were negative. During the first week the baby developed sepsis in the form of feed intolerance and severe thrombocytopenia. The 2nd blood culture sent on day 9 of life grew *Klebsiella pneumoniae* sensitive to carbapenems and colistin. Hence umbilical venous line was removed and antibiotics were changed to Meropenem and IV Fluconazole (12mg/kg loading dose followed by 6 mg/kg daily) was also added prophylactically. Even after 48 hours of antibiotics, laboratory and clinical findings showed no improvement. Platelet transfusion and immunoglobulin were given in view of sepsis. Antibiotic was changed to Colistimethate sodium. In spite of this improvement was very gradual, baby persistently had thrombocytopenia and mild tachypnea. A strong suspicion of fungal septicemia was kept in mind and

a 3rd blood culture was sent on day 18 of life which grew budding yeast cells, and liposomal Amphotericin B was immediately added starting with dose of 1 mg/kg/day and Fluconazole was stopped. Liposomal amphotericin B was preferred over conventional amphotericin B in view of its safety profile and better efficacy. A blood culture done with BioMerieux Bact/ALERT Automated microbial detection system using Bact/ALERT FA plus culture bottles, testing was positive for *Kodamaea ohmeri*. Microbiological workup done with BioMerieux VITEK II compact automated system using Vitek 2 YST card for identification and AST YS06 card for antifungal susceptibility test confirmed the yeast isolate as *Kodamaea ohmeri*. Chrome agar culture of *K.ohmeri* depicted colour change from white to slight pink on extended incubation of more than 48 hours. The sensitivity pattern revealed susceptibility to Amphotericin B (MIC <0.5), caspofungin (MIC<0.25) and Flucytosine (MIC<1) but resistance to fluconazole. Meningitis and endocarditis were ruled out by cerebrospinal fluid (CSF) examination and echocardiography respectively. Ultrasound of brain was normal done on day 5 of life. However the subsequent ultrasound done on day 12 of life was suggestive of grade 1 bilateral germinal matrix hemorrhage which resolved on follow up. Renal parameters and ophthalmic examination were also normal. Within 48 hours of treatment, baby showed clinical and laboratory improvement as shown in table 1, so further microbiological investigations were not performed. Colistimethate sodium and Amphotericin B were continued for 14 days. Repeat blood culture on day 9 of Amphotericin B was sterile. Baby is on regular follow up and doing well without any deficit.

**Discussion**

*Kodamaea ohmeri*, formerly known as *Pichia ohmeri* or *Yamadazyma ohmeri*, is a scosporogenic yeast which usually occurs in the haploid state within the family of Saccharomycetaceae. (7) The genus *Kodamaea* currently comprises five species: *K. anthrophila*, *K. kakaduensis*, *K. laetipori*, *K. nitidularum*, and *K. ohmeri*. (8) *Kodamaea ohmeri* is a rare clinical isolate

that has recently become known to cause various human infections. This yeast is commonly used in the food industry for its fermentation properties in pickles. (2) Review of literature reveals that immunocompromised state especially with breakdown of the skin mucosal barrier, presence of invasive devices and prematurity are risk factors for this infection. (1,2,4) Very limited cases of *K.Ohmeri* fungemia are known. (2-6)

With recent advance in care of preterm newborns, a significant number of them survive leading to an increase in the prevalence of fungal infections during infancy. All these infections in newborns have taken place in preterm neonates with invasive devices in the form of umbilical venous lines, multiple intravenous injections and in babies who have been on broad spectrum antibiotics like in our case. (2-6) The clinical spectrum in adults range from fungemia to endocarditis, peritonitis, wound infection and phlebitis.(1) However the case reports in newborns have suggested mainly fungemia and one case of tricuspid valve endocarditis with fungemia as the forms of clinical manifestations in neonates. (2-6)

The early identification of fungal infections is crucial for proper treatment. (9) *K.ohmeri* isolate usually exhibits a characteristic color change from pink to blue over a 48-hours period on CHROMagar Candida medium. Lee et al suggested Vitek II in adjunct with chromagar could be immensely helpful for identification of *kodamaea ohmeri*. (3)The new VITEK 2 system is a fully automated system dedicated to the identification and susceptibility testing of microorganisms. In conjunction with the VITEK ID-YST card the VITEK 2 system allows the identification of clinically important yeasts and yeast-like organisms in 15 hours due to a sensitive fluorescence-based technology as in our case. The sequence analysis is useful for a definitive species identification of *K. ohmeri* isolates.(9)

Presently the treatment strategy includes removal of invasive devices and use of effective antifungal therapy. Many studies regarding the susceptibility of *Kodamaea* to various antifungal therapy have been conducted. (5,6,10) These studies have concluded the superiority

**Table 1: Serial laboratory parameters of the patient**

Laboratory Parameter	Day 1	Day 3	Day 8	Day 13 (Meropenem started)	Day 15 (Colistin started)	Day 20 (Liposomal Amphotericin B started)	Day 28	Day 35
Hemoglobin (g/dl)	17.1	21.4	21.4	13.4	13	11.5	7.6	10.5
White cell count (cells/cu mm)	12400	14600	7500	6900	13600	12800	11500	14800
Platelets (cells/cumm)	107000	32000	39000	18000	20000	17000	65000	116000
Serum Creatinine (mg/dl)					0.9		0.5	0.6

of amphotericin B over the azole group of drugs although a dose dependent response may be present with azole group in some isolates. Our neonate was already on fluconazole yet showed no improvement. The addition of liposomal amphotericin B in the treatment regime resulted in clinical and hematological improvement. Lipid formulated amphotericin B has several advantages over conventional amphotericin B, including an increased daily dosage of the parent drug (up to 10-fold), high tissue concentrations in the primary reticuloendothelial organs (lungs, liver, and spleen), a decrease in infusion-related side effects (especially liposomal amphotericin B), and a marked decrease in renal toxicity. The dose ranged from 1mg/kg/day to a maximum of 5mg/day based on the clinical response. (10) Because of high mortality and unawareness of *K.ohmeri*, we recommend early and accurate identification of this potentially fatal pathogen and timely interventions like removal of any implanted device and use of liposomal amphotericin B over 14 days for its complete eradication.

#### Acknowledgement

Authors would also like to thanks Dr. Parvez Inamdar, Medical director, Inamdar Multispecialty Hospital, Pune for allowing us to publish this case.

**Funding:** None

**Conflict of Interest :** None

#### References :

1. Yang BH, Peng MY, Hou SJ, Sun JR, Lee SY, Lu JJ. Fluconazole-resistant *Kodamaea ohmeri* fungemia associated with cellulitis: case report and review of the literature. *Int J Infect Dis.* 2009 ;13:e493-497
2. Taj-Aldeen SJ, Doiphode SH, Han XY. *Kodamaea* [Pichia] *ohmeri* fungaemia in a premature neonate. *J Med Microbiol.* 2006;55:237-239.
3. Lee JS, Shin JH, KimMN, Jung SI, Park KH, Cho D, et al. *Kodamaea ohmeri* isolates from patients in a university hospital: identification, antifungal susceptibility, and pulse-field gel electrophoresis analysis. *J Clin Microbiol.* 2007;45:1005-1010.
4. Poojary A, Sapre G. *Kodamaea ohmeri* Infection in a Neonate. *Indian Pediatr.* 2009;46:629-631
5. Sundaram PS, Bijulal S, Tharakan JA , Antony M. *Kodamaea ohmeri* tricuspid valve endocarditis with right ventricular inflow obstruction in a neonate with structurally normal heart. *Ann Pediatr Cardiol.* 2011; 4: 77-80.
6. Al-Sweih N, Khan ZU, Ahmad S, Devarajan L, Khan S, Joseph L, et al. *Kodamaea ohmeri* as an emerging pathogen: a case report and review of the literature. *Med Mycol.* 2011;49:766-770
7. Yamada Y, Suzuki T, Matsuda M, Mikata K. The phylogeny of *Yamadazyma ohmeri* [Etchells et Bell] Billon-Grand based on the partial sequences of 18S and 26S ribosomal RNAs: the proposal of *Kodamaea* gen. nov. [Saccharomycetaceae]. *Biosci Biotechnol Biochem* 1995;59:1172-1174.
8. Kurtzman CP. In: Kurtzman C P, Fell J W, editors. *The yeasts: a taxonomic study.* 4th ed. Amsterdam. The Netherlands. Elsevier Science Publishers. 1998: 23-26.
9. Graf B, Adam T, Zill E, Göbel UB. Evaluation of the VITEK2 System for Rapid Identification of Yeasts and Yeast-Like Organisms. *J Clin Microbiol.* 2000; 38: 1782-1785
10. Jeon GW, Koo SH, Lee JH, Hwang JH, Kim SS, Lee EK, et al. A comparison of AmBisome to amphotericin B for treatment of systemic candidiasis in very low birth weight infants. *Yonsei Med J.* 2007;48:619-626

---

**From:** \*Department of Pediatrics and Neonatology and  
\*\*Department of Microbiology, Inamdar Multispecialty Hospital, Pune, Maharashtra, India.

**Address for Correspondence:** Dr. Ashwin Borade, Consultant Pediatrician and Neonatologist, Inamdar Multispecialty Hospital, Street no 15, Fatima Nagar, Pune, Maharashtra, India 411040.

**Email:** ashwinborade@yahoo.com



---

**DOI No.** 10.7199/ped.oncall.2014.66

---